REGENXBIO

regenxbio-logo

REGENX Biosciences is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart fa... ilure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity, and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia.

#People #Financial #Website #More

REGENXBIO

Social Links:

Industry:
Biopharma Biotechnology Genetics Therapeutics

Founded:
2009-01-01

Address:
Rockville, Maryland, United States

Country:
United States

Website Url:
http://www.regenxbio.com

Total Employee:
251+

Status:
Active

Contact:
(202) 785-7438

Email Addresses:
[email protected]

Total Funding:
638.19 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager WordPress Google Universal Analytics Font Awesome



Current Advisors List

alexandra-glucksmann_image

Alexandra Glucksmann Independent Board Member @ REGENXBIO
Board_member
2018-05-01

camille-samuels_image

Camille Samuels Member of the Board of Directors @ REGENXBIO
Board_member

Current Employees Featured

kenneth-mills_image

Kenneth Mills
Kenneth Mills Chief Executive Officer, President and Director @ REGENXBIO
Chief Executive Officer, President and Director
2009-02-01

ken-mills_image

Ken Mills
Ken Mills President & Chief Executive Officer @ REGENXBIO
President & Chief Executive Officer

vit-vasista_image

Vit Vasista
Vit Vasista CFO @ REGENXBIO
CFO
2009-07-01

curran-m-simpson_image

Curran M. Simpson
Curran M. Simpson Senior Vice President of Product Development & Chief Technology Officer @ REGENXBIO
Senior Vice President of Product Development & Chief Technology Officer

olivier-danos_image

Olivier Danos
Olivier Danos Senior Vice President & Chief Scientific Officer @ REGENXBIO
Senior Vice President & Chief Scientific Officer

steve-pakola_image

Steve Pakola
Steve Pakola Senior Vice President & Chief Medical Officer @ REGENXBIO
Senior Vice President & Chief Medical Officer

francesca-cook_image

Francesca Cook
Francesca Cook Vice President, Market Access @ REGENXBIO
Vice President, Market Access
2021-03-01

ram-palanki_image

Ram Palanki
Ram Palanki Senior Vice President, Commercial Strategy & Operations @ REGENXBIO
Senior Vice President, Commercial Strategy & Operations
2018-08-01

not_available_image

James M. Wilson
James M. Wilson Founder & Chief Scientific Advisor @ REGENXBIO
Founder & Chief Scientific Advisor

olivier-danos_image

Olivier Danos
Olivier Danos Chief Scientific Officer @ REGENXBIO
Chief Scientific Officer
2017-03-01

Founder


james-brown_image

James Brown

not_available_image

James M. Wilson

kenneth-mills_image

Kenneth Mills

Stock Details


Company's stock symbol is NASDAQ:RGNX

Acquisitions List

Date Company Article Price
2017-08-25 Dimension Therapeutics Dimension Therapeutics acquired by REGENXBIO N/A

Investors List

frazier-healthcare-ventures_image

Frazier Healthcare Partners

Frazier Healthcare Partners investment in Post-IPO Equity - REGENXBIO

rtw-investments-llc_image

RTW Investments LLC

RTW Investments LLC investment in Series D - REGENXBIO

foresite-capital_image

Foresite Capital

Foresite Capital investment in Series D - REGENXBIO

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Series D - REGENXBIO

sectoral-asset-management_image

Sectoral Asset Management

Sectoral Asset Management investment in Series D - REGENXBIO

venrock_image

Venrock

Venrock investment in Series D - REGENXBIO

cormorant-asset-management_image

Cormorant Asset Management

Cormorant Asset Management investment in Series D - REGENXBIO

qvt-financial_image

QVT Financial

QVT Financial investment in Series D - REGENXBIO

f-prime-capital-partners_image

F-Prime Capital

F-Prime Capital investment in Series D - REGENXBIO

tourbillon-global-ventures_image

Tourbillon Global Ventures

Tourbillon Global Ventures investment in Series D - REGENXBIO

Official Site Inspections

http://www.regenxbio.com Semrush global rank: 1.53 M Semrush visits lastest month: 17.31 K

  • Host name: 20.231.205.235
  • IP address: 20.231.205.235
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "REGENXBIO" on Search Engine